Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Denis Smith

Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) Chemotherapy in the Treatment of Metastatic or Unresectable Locally Recurrent Anal Squamous Cell Carcinoma: A Phase II Study of French Interdisciplinary GERCOR and FFCD Groups (Epitopes-Hpv02 Study)

BMC Cancer

English

Phase III Trial of Chemotherapy Using 5-Fluorouracil and Streptozotocin Compared With Interferon for Advanced Carcinoid Tumors: FNCLCC-FFCD 9710

Endocrine-Related Cancer

English

Related publications

Phase II Study of Docetaxel and Irinotecan Combination Chemotherapy in Metastatic Gastric Carcinoma

British Journal of Cancer

Cancer Research

Oncology

2006

English

A Phase II Evaluation of a 3-Hour Infusion of Paclitaxel, Cisplatin, and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

English

Weekly Chemotherapy of 5‐Fluorouracil Plus Cisplatin Concurrent With Radiotherapy for Esophageal Squamous Cell Carcinoma Patients With Postoperative Locoregional Recurrence: Results From a Phase II Study

English

Induction With Mitomycin C, Doxorubicin, Cisplatin and Maintenance With Weekly 5-Fluorouracil, Leucovorin for Treatment of Metastatic Nasopharyngeal Carcinoma: A Phase II Study

British Journal of Cancer

Cancer Research

Oncology

1999

English

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/Ii Clinical Study

English

A Phase II Study of Temsirolimus and Erlotinib in Patients With Recurrent and/or Metastatic, Platinum-Refractory Head and Neck Squamous Cell Carcinoma

English

Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma

English

A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer

Oncotarget

Oncology

2020

English

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs

Oncology

Pharmacology

2011

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Denis Smith

Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) Chemotherapy in the Treatment of Metastatic or Unresectable Locally Recurrent Anal Squamous Cell Carcinoma: A Phase II Study of French Interdisciplinary GERCOR and FFCD Groups (Epitopes-Hpv02 Study)

Phase III Trial of Chemotherapy Using 5-Fluorouracil and Streptozotocin Compared With Interferon for Advanced Carcinoid Tumors: FNCLCC-FFCD 9710

Related publications

Phase II Study of Docetaxel and Irinotecan Combination Chemotherapy in Metastatic Gastric Carcinoma

A Phase II Evaluation of a 3-Hour Infusion of Paclitaxel, Cisplatin, and 5-Fluorouracil in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Weekly Chemotherapy of 5‐Fluorouracil Plus Cisplatin Concurrent With Radiotherapy for Esophageal Squamous Cell Carcinoma Patients With Postoperative Locoregional Recurrence: Results From a Phase II Study

Induction With Mitomycin C, Doxorubicin, Cisplatin and Maintenance With Weekly 5-Fluorouracil, Leucovorin for Treatment of Metastatic Nasopharyngeal Carcinoma: A Phase II Study

Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/Ii Clinical Study

A Phase II Study of Temsirolimus and Erlotinib in Patients With Recurrent and/or Metastatic, Platinum-Refractory Head and Neck Squamous Cell Carcinoma

Adoptive T-Cell Transfer and Chemotherapy in the First-Line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma

A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer

SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma